Neil Portman
7 Eliza Street
Newtown, NSW 2042, Australia
Newtown, NSW 2042, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer.
Journal: Journal of experimental & clinical cancer research : CR
Published: April 15, 2025
Characterising the effect of circulating sphingolipids on metastatic prostate cancer cells.
Journal: EBioMedicine
Published: January 22, 2025
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 16, 2024
Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance.
Journal: The Journal of clinical investigation
Published: June 05, 2024
The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer.
The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer.
Journal: Nature structural & molecular biology
Published: December 13, 2022
Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor.
Journal: Cancer communications (London, England)
Published: December 05, 2022
Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
Journal: Nature communications
Published: September 17, 2021
MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer.
Journal: Frontiers in oncology
Published: September 17, 2021
Last Updated: 09/26/2026